Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?
Conclusion: In this patient cohort, pazopanib was associated with inferior OS in comparison with sunitinib for metastatic nccRCC. Larger trials are ideally warranted to confirm these results.
PMID: 31921344 [PubMed]
Source: Ecancermedicalscience - Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research
More News: Academia | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Databases & Libraries | Kidney Cancer | Renal Cell Carcinoma | Translocation